Yahoo Finance

Iovance Biotherapeutics stock was tumbling Friday after the oncology drug maker posted a wider-than-expected first-quarter loss. Management pinned the disappointing first-quarter results on reduced production capacity due to annual maintenance at its Iovance Cell Therapy Center. “Since full production has now resumed at the [Cell Therapy Center], we now expect infusions to grow in the second quarter as compared to the first quarter,” said interim CEO Frederick Vogt.